Lung Cancer

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses data of lurbinectedin plus doxorubicin as a second-line therapy for patients with small cell lung cancer.

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the mechanisms behind immune-related adverse events (irAEs) in lung cancer.

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses sequencing strategies for patients with ALK-positive non–small cell lung cancer (NSCLC).

Jose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the treatment of patients with oligometastatic non–small cell lung cancer.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

The FDA has approved dacomitinib (Vizimpro) for the frontline treatment of patients with metastatic non–small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), a 2017 Giant of Cancer Care® in Lung Cancer, discusses the idea for an online treatment decision tool for lung cancer.

Geoffrey R. Oxnard, MD, discusses the promise of genome-wide sequencing in cell-free DNA.

Laurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.

Lurbinectedin plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer, especially when excluding refractory patients.

Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.

Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing for patients with metastatic non–small cell lung cancer.